Treatment of acute urinary retention

Details Treatment of acute urinary retention Treatment of acute urinary retention

1995-02-21

1996-10-01

Spivack, Phyllis G.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

A61K 31135, A61K 3121

Patent

active

055611540

ABSTRACT:
This invention is concerned with a composition and method for the treatment of acute urinary retention, whereby deacetyl moxisylyte or one of its non-toxic salts is administered in a ready to use aqueous solution by the intravenous route to induce a decrease in the urethral contractility.

REFERENCES:
patent: 5182270 (1993-01-01), Musson et al.
Vidal 1993 (dictionary), 69th Edition, Editions du Vidal, Paris 1993, pp. 9, 689 and 1489-1490.
"In Vitro and In Vivo .alpha.-Blocking Activity of Thymoxamine and Its Two Metabolites", M. H. Creuzet, et al., J. Pharm. Pharmacol. 1980, vol. 32, pp. 209-213.
".alpha..sub.1 -and .alpha..sub.2 -Adrenoceptor Selectivity of Moxisylyte (Thymoxamine) and Its Metabolites in the Pithed Rat", J. Roquebert, et al., Arch. Int. Pharmacodyn, 1983, vol. 266, pp. 282-293.
Poirier et al., J. Urol. (Baltimore) (1988), 140(1), 165-7.

Affiliated with

Also associated with

Rating

Treatment of acute urinary retention does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of acute urinary retention, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of acute urinary retention will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1502203